{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-036109","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.708867+00:00","generated_at":"2026-05-23T04:45:22.666928+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share","bullets":["Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.","Oramed gets right to nominate two directors to Alpha Tau board; board size capped at 8 without Oramed's consent.","Concurrent 3-year IR/PR services agreement; Oramed receives $3M fee plus warrants to buy ~3.24M shares at $3.474-$3.90.","Partnership aims to support Alpha Tau's alpha-radiation cancer therapy Alpha DaRT, including US trials and manufacturing scale-up.","Oramed CEO Nadav Kidron cites alignment in transforming therapeutic delivery; governance role allows strategic influence."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-036109","json":"https://secwatch.observer/filing/0001213900-25-036109.json","markdown":"https://secwatch.observer/filing/0001213900-25-036109.md","text":"https://secwatch.observer/filing/0001213900-25-036109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/0001213900-25-036109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/ea0239800-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:45:22.666928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}